Taking a Closer Look at Cognitive Decline and Preclinical Alzheimer’s Disease

Dr. Reisa Sperling returns for another episode of Dementia Matters. After covering her research focused on preclinical Alzheimer’s disease in part one, Dr. Sperling dives deeper into the different factors that can impact cognitive decline and early-stage Alzheimer’s disease and how clinical trials are shaping the field’s understanding of detecting, treating and preventing the disease. Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer’s Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School   Show Notes Listen to our first episode with Dr. Sperling, “Defining and Addressing Preclinical Alzheimer’s Disease,” on Spotify, Apple Podcasts and on our website. Read more about the Harvard Aging Brains Study on their website. Read more about the AHEAD Study on their website. Watch “Voices from the AHEAD Alzheimer’s Disease Trial,” featuring Dr. Cynthia Carlsson and a research participant, on YouTube.  Learn more about the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) study here. Learn more about Dr. Sperling in her profile on the Massachusetts General Hospital website.   Connect with us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

There are no comments yet.

Please log in to write the first comment.